Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma (Q36492327)

14 August 2017

1 reference

title

Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma (English)

1 reference

14 August 2017

1 reference

1 reference

Myke R Green

1 reference

14 August 2017

Sajeel Chowdhary

1 reference

14 August 2017

Kristina M Lombardi

1 reference

14 August 2017

Lisa M Chalmers

1 reference

14 August 2017

Marc Chamberlain

1 reference

14 August 2017

language of work or name

1 reference

1 May 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

635-652

1 reference

Trends in incidence of primary malignant brain tumors in USA, 1981-1990.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Epidemiology of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Popula

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Solitary primary CNS lymphoma: long term survival following total resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Delayed neurotoxicity in primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary central nervous system lymphoma: a curable brain tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Treatment for primary CNS lymphoma: the next step

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Combined modality therapy for primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Methotrexate-induced misincorporation of uracil into DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Receptor-mediated folate accumulation is regulated by the cellular folate content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

A mechanism of resistance to methotrexate. NADPH but not NADH stimulation of methotrexate binding to dihydrofolate reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Stereospecificity at carbon 6 of fomyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

New vistas for leucovorin in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Pharmacokinetics of Methotrexate in Plasma and Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Effect of pleural effusion on high-dose methotrexate kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Effective clearance of methotrexate using high-flux hemodialysis membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Anaphylactoid reactions to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Resistance to antifolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Intrinsic and acquired resistance to methotrexate in acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Leucovorin rescue revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Methotrexate: clinical pharmacology, current status and therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Folate status and the safety profile of antifolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Polyglutamation of methotrexate. Is methotrexate a prodrug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Treatment of primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Disposition of high-dose methotrexate in an obese cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

The cellular pharmacology of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Low-grade primary central nervous system lymphoma in immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Pharmacotherapy of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

Primary nervous-system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.5.635

21 January 2018

Identifiers

DOI

10.1586/14737175.6.5.635

1 reference

14 August 2017

1 reference